OBJECTIVE： To explore the clinical efficacy and safety of cetuximab combined with NP regimen and radiotherapy in the treatment of advanced non-small cell lung cancer（NSCLC）. METHODS： 76 cases of advanced NSCLC were selected and randomly divided into control group and observation group according to different therapy methods， with 38 cases in each group. Control group received NP regimen （cisplatin 25 mg/m2 + navelbine 12.5 mg/m2）+thoracic IMRT； observation group was additionally given cetuximab 400 mg/m2 （first day）， with maintenance dose of 250 mg/m2 weekly and last for 13 weeks. Short-term efficacy， survival situation were compared between 2 groups as well as the levels of T lymphocyte， Th1， Th2， immuneglobulin（Ig） and complement. The occurrence of ADR was recorded. RESULTS： The total effective rate of observation group was 86.84％， which was significantly higher than that of control group （65.79％）， with statistical significance （P＜0.05）. Average survival period and 2-year survival rate of observation group were 18.70 months and 55.26％， which were significantly longer or higher than those of control group （14.75 months， 31.58％）， with statistical significance （P＜0.05）. The improvement rate of survival quality was 94.74％ in observation group， which was significantly higher than 68.42％ in control group， with statistical significance （P＜0.05）. After treatment， the levels of CD4+， CD4+/CD8+ and IgG were significantly increased in 2 groups， while the levels of CD8+， Th1， Th2 and Th1/Th2 were significantly decreased； the observation group was better than the control group， with statistical significance （P＜0.05）； there was no statistical significance in the levels of CD3+， IgA， IgM and complement 4 between 2 groups （P＞0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Cetuximab combined with NP regimen and radiotherapy can improve clinical efficacy of advanced NSCLC， improve survival quality， prolong survival time and promote the recovery of Ig， complement and T lymphocyte， with good safety.